Precision AQ

Ruby WangSenior Analyst

Ruoding (Ruby) Wang advises pharmaceutical and biotechnology companies on pricing and market access, with an expertise on China-specific strategies. Her experience spans policy analysis, NRDL strategy and negotiation, value message communication, alternative payment pathways, and early access and lifecycle planning. Prior to joining Precision AQ, she spent four years at IQVIA China supporting pricing and market access strategy as well as policy-driven decision-making. Ruby holds a Master of Public Administration degree in Health Services Management from New York University.

Let's talk

Insights from Ruby Wang

China Market Access After NRDL Maturity: What Comes After the Price Reset? Image

Commercialization & Access | White Paper China Market Access After NRDL Maturity: What Comes After the Price Reset? NRDL inclusion is no longer the finish line. See why reimbursement alone doesn’t guarantee real-world utilization.